Circulating miRNAs as biomarkers for neurodegenerative disorders

Molecules

Volumn 19, Issue 5, 2014, Pages 6891-6910

  Grasso, Margherita ^a   Piscopo, Paola ^b   Confaloni, Annamaria ^b   Denti, Michela A ^a,c  

^a UNIVERSITY OF TRENTO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CNR   (Italy)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Biomarkers; MiRNAs; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ALZHEIMER DISEASE; GENETICS; HUMAN; METABOLISM; NEOPLASM; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MICRORNAS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84901430095     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19056891     Document Type: Review

References (103)

1. miRBase Sequence Database. Available online: http://microrna.sanger.ac. uk/sequences (accessed on 23 May 2014).
2. Kozomara A.; Griffiths-Jones S. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39, D152-D157.
3. Ambros V.; Bartel B.; Bartel D.P.; Burge C.B.; Carrington J.C.; Chen X.; Dreyfuss G.; Eddy S.R.; Griffiths-Jones S.; Marshall M.; et al. A uniform system for microRNA annotation. RNA 2003, 9, 277-279.
4. Chalfie M.; Horvitz H.R.; Sulston J.E. Mutations that lead to reiterations in the cell lineages of C. elegans. Cell 1981, 24, 59-69.
5. Lee R.C.; Feinbaum R.L.; Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854.
6. Olsen P.H.; Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev. Biol. 1999, 216, 671-680.
7. Wightman B.; Ha I.; Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75, 855-862.
8. Bartel D.P. microRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
9. Lewis B.P.; Burge C.B.; Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15-20.
10. Lytle J.R.; Yario T.A.; Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5'UTR as in the 3'UTR. Proc. Natl. Acad. Sci. USA 2007, 104, 9667-9672.
11. Lee I.; Ajay S.S.; Yook J.I.; Kim H.S.; Hong S.H.; Kim N.H.; Dhanasekaran S.M.; Chinnaiyan A.M.; Athey B.D. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res. 2009, 19, 1175-1183.
12. Zhou X.; Duan X.; Qian J.; Li F. Abundant conserved microRNA target sites in the 5' untranslated region and coding sequence. Genetica 2009, 137, 159-164.
13. Hausser J.; Syed A.P.; Bilen B.; Zavolan M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013, 23, 604-615.
14. Lee Y.; Ahn C.; Han J.; Choi H.; Kim J.; Yim J.; Lee J.; Provost P.; Rådmark O.; Kim S.; et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425, 415-419.
15. Denli A.M.; Tops B.B.; Plasterk R.H.; Ketting R.F.; Hannon G.J. Processing of primary microRNAs by the Microprocessor complex. Nature 2004, 432, 231-235.
16. Winter J.; Diederichs S. microRNA Northern blotting, precursor cloning, and Ago2-improved RNA interference. Methods Mol. Biol. 2011, 676, 85-100.
17. Cullen B.R. Derivation and function of small interfering RNAs and microRNAs. Virus Res. 2004, 102, 3-9.
18. Winter J.; Link S.; Witzigmann D.; Hildenbrand C.; Previti C.; Diederichs S. Loop-miRs: Active microRNAs generated from single-stranded loop regions. Nucleic Acids Res. 2013, 10, 5503-5512.
19. Goodall E.F.; Heath P.R.; Bandmann O.; Kirby J.; Shaw P.J. Neuronal dark matter: The emerging role of microRNAs in neurodegeneration. Front. Cell. Neurosci. 2013, 7, 178.
20. Shafi G.; Aliya N.; Munshi A. microRNA signatures in neurological disorders. Can. J. Neurol. Sci. 2010, 37, 177-185.
21. Langbaum J.B.; Fleisher A.S.; Chen K.; Ayutyanont N.; Lopera F.; Quiroz Y.T.; Caselli R.J.; Tariot P.N.; Reiman E.M. Ushering in the study and treatment of preclinical Alzheimer disease. Nat. Rev. Neurol. 2013, 9, 371-381.
22. Schapira A.H. Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 2013, 26, 395-400.
23. Keller A.; Leidinger P.; Bauer A.; Elsharawy A.; Haas J.; Backes C.; Wendschlag A.; Giese N.; Tjaden C.; Ott K.; et al. Toward the blood-borne miRNome of human diseases. Nat. Methods 2011, 8, 841-843.
24. Lawrie C.H.; Gal S.; Dunlop H.M.; Pushkaran B.; Liggins A.P.; Pulford K.; Banham A.H.; Pezzella F.; Boultwood J.; Wainscoat J.S.; et al. Detection of elevated levels of tumour-Associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141, 672-675.
25. Gilad S.; Meiri E.; Yogev Y.; Benjamin S.; Lebanony D.; Yerushalmi N.; Benjamin H.; Kushnir M.; Cholakh H.; Melamed N.; et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3, e3148.
26. Zen K.; Zhang C.Y. Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 2012, 32, 326-348.
27. Valadi H.; Ekström K.; Bossios A.; Sjöstrand M.; Lee J.J.; Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
28. Hunter M.P.; Ismail N.; Zhang X.; Aguda B.D.; Lee E.J.; Yu L.; Xiao T.; Schafer J.; Lee M.T.; Schmittgen T.D.; et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3, e3694.
29. Zernecke A.; Bidzhekov K.; Noels H.; Shagdarsuren E.; Gan L.; Denecke B.; Hristov M.; Köppel T.; Jahantigh M.N.; Lutgens E.; et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2009, 2, ra81.
30. Wang K.; Zhang S.; Weber J.; Baxter D.; Galas D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acid Res. 2010, 38, 7248-7259.
31. Vickers K.C.; Palmisano B.T.; Shoucri B.M.; Shamburek R.D.; Remaley A.T. microRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423-433.
32. Xi Y.; Nakajima G.; Gavin E.; Morris C.G.; Kudo K.; Hayashi K.; Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13, 1668-1674.
33. Mizuno H.; Nakamura A.; Aoki Y.; Ito N.; Kishi S.; Yamamoto K.; Sekiguchi M.; Takeda S.; Hashido K. Identification of musclespecific microRNAs in serum of muscular dystrophy animal models: Promising novel blood-based markers for muscular dystrophy. PLoS One 2011, 6, e18388.
34. Cuk K.; Zucknick M.; Heil J.; Madhavan D.; Schott S.; Turchinovich A.; Arlt D.; Rath M.; Sohn C.; Benner A.; et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer 2013, 132, 1602-1612.
35. Bateman R.J.; Xiong C.; Benzinger T.L.; Fagan A.M.; Goate A.; Fox N.C.; Marcus D.S.; Cairns N.J.; Xie X.; Blazey T.M.; et al. The Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367, 795-804.
36. Craig-Schapiro R.; Fagan A.M.; Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 2009, 35, 128-140.
37. Hebert S.S.; Horre K.; Nicolai L.; Papadopoulou A.S.; Mandemakers W.; Silahtaroglu A.N.; Kauppinen S.; Delacourte A.; de Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. USA 2008, 105, 6415-6420.
38. Wang W.X.; Rajeev B.W.; Stromberg A.J.; Ren N.; Tang G.; Huang Q.; Rigoutsos I.; Nelson P.T. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor proteincleaving enzyme 1. J. Neurosci. 2008, 28, 1213-1223.
39. Geekiyanage H.; Chan C. microRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease. J. Neurosci. 2011, 31, 14820-14830.
40. Long J.M.; Lahiri D.K. microRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Commun. 2010, 404, 889-895.
41. Schipper H.M.; Maes O.C.; Chertkow H.M.; Wang E. microRNA expression in Alzheimer blood mononuclear cells. Gene Regul. Syst. Biol. 2007, 1, 263-274.
42. Leidinger P.; Backes C.; Deutscher S.; Schmitt K.; Mueller S.C.; Frese K.; Haas J.; Ruprecht K.; Paul F.; Stähler C.; et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013, 14, R78.
43. Kumar P.; Dezso Z.; MacKenzie C.; Oestreicher J.; Agoulnik S.; Byrne M.; Bernier F.; Yanagimachi M.; Aoshima K.; Oda Y. Circulating miRNA biomarkers for Alzheimer's disease. PLoS One 2013, 8, e69807.
44. Sala Frigerio C.; Lau P.; Salta E.; Tournoy J.; Bossers K.; Vandenberghe R.; Wallin A.; Bjerke M.; Zetterberg H.; Blennow K.; et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 2013, 81, 2103-2106.
45. Cogswell J.P.; Ward J.; Taylor I.A.; Waters M.; Shi Y.; Cannon B.; Kelnar K.; Kemppainen J.; Brown D.; Chen C.; et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 2008, 14, 27-41.
46. Alexandrov P.N.; Dua P.; Hill J.M.; Bhattacharjee S.; Zhao Y.; Lukiw W.J. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 2012, 3, 365-373.
47. Lukiw W.J.; Alexandrov P.N.; Zhao Y.; Hill J.M.; Bhattacharjee S. Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport 2012, 23, 621-626.
48. Lehmann S.M.; Krüger C.; Park B.; Derkow K.; Rosenberger K.; Baumgart J.; Trimbuch T.; Eom G.; Hinz M.; Kaul D.; et al. An unconventional role for miRNA: Let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 2012, 15, 827-835.
49. Bekris L.M.; Lutz F.; Montine T.J.; Yu C.E.; Tsuang D.; Peskind E.R.; Leverenz J.B. microRNA in Alzheimer's disease: An exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 2013, 18, 455-466.
50. Geekiyanage H.; Jicha G.A.; Nelson P.T.; Chan C. Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp. Neurol. 2012, 235, 491-496.
51. Bhatnagar S.; Chertkow H.; Schipper H.M.; Yuan Z.; Shetty V.; Jenkins S.; Jones T.; Wang E. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Front. Mol. Neurosci. 2014, 7, 2.
52. DeCarli C. Mild cognitive impairment: Prevalence, prognosis, etiology, and treatment. Lancet Neurol. 2003, 2, 15-21.
53. Sheinerman K.S.; Tsivinsky V.G.; Crawford F.; Mullan M.J.; Abdullah L.; Umansky S.R. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany N. Y.) 2012, 4, 590-605.
54. Nuytemans K.; Theuns J.; Cruts M.; van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum. Mutat. 2010, 31, 763-780.
55. Coppedè F. Genetics and epigenetics of Parkinson's disease. Sci. World J. 2012, 2012, 489830.
56. Hong Z.; Shi M.; Chung K.A.; Quinn J.F.; Peskind E.R.; Galasko D.; Jankovic J.; Zabetian C.P.; Leverenz J.B.; Baird G.; et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133, 713-726.
57. Martins M.; Rosa A.; Guedes L.C.; Fonseca B.V.; Gotovac K.; Violante S.; Mestre T.; Coelho M.; Rosa M.M.; Martin E.R.; et al. Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease. PLoS One 2011, 6, e25443.
58. Margis R.; Rieder C.R. Identification of blood microRNAs associated to Parkinson's disease. J. Biotechnol. 2011, 152, 96-101.
59. Cardo L.F.; Coto E.; de Mena L.; Ribacoba R.; Moris G.; Menéndez M.; Alvarez V. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J. Neurol. 2013, 260, 1420-1422.
60. Khoo S.K.; Petillo D.; Kang U.J.; Resau J.H.; Berryhill B.; Linder J.; Forsgren L.; Neuman L.A.; Tan A.C. Plasma-based circulating microRNA biomarkers for Parkinson's disease. J. Parkinsons Dis. 2012, 2, 321-331.
61. Soreq L.; Salomonis N.; Bronstein M.; Greenberg D.S.; Israel Z.; Bergman H.; Soreq H. Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front. Mol. Neurosci. 2013, 6, 10.
62. Turner M.R.; Kiernan M.C.; Leigh P.N.; Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009, 8, 94-109.
63. Ryberg H. Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev. Proteomics 2008, 5, 249-262.
64. De Felice B.; Guida M.; Guida M.; Coppola C.; de Mieri G.; Cotrufo R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012, 508, 35-40.
65. Butovsky O.; Siddiqui S.; Gabriely G.; Lanser A.J.; Dake B.; Murugaiyan G.; Doykan C.E.; Wu P.M.; Gali R.R.; Iyer L.K.; et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Investig. 2012, 122, 3063-3087.
66. Gaughwin P.M.; Ciesla M.; Lahiri N.; Tabrizi S.J.; Brundin P.; Björkqvist M. Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum. Mol. Genet. 2011, 20, 2225-2237.
67. Minones-Moyano E.; Porta S.; Escaramis G.; Rabionet R.; Iraola S.; Kagerbauer B.; Espinosa-Parrilla Y.; Ferrer I.; Estivill X.; Marti E. microRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011, 20, 3067-3078.
68. Du L.; Pertsemlidis A. Cancer and neurodegenerative disorders: Pathogenic convergence through microRNA regulation. J. Mol. Cell Biol. 2011, 3, 176-180.
69. Podlisny M.B.; Lee G.; Selkoe D.J. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science 1987, 238, 669-671.
70. Rovelet-Lecrux A.; Hannequin D.; Raux G.; le Meur N.; Laquerrière A.; Vital A.; Dumanchin C.; Feuillette S.; Brice A.; Vercelletto M.; et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006, 38, 24-26.
71. Theuns J.; Brouwers N.; Engelborghs S.; Sleegers K.; Bogaerts V.; Corsmit E.; de Pooter T.; van Duijn C.M.; de Deyn P.P.; van Broeckhoven C. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am. J. Hum. Genet. 2006, 78, 936-946.
72. LaFerla F.M.; Green K.N.; Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8, 499-509.
73. Hansel D.E.; Rahman A.; Wehner S.; Herzog V.; Yeo C.J.; Maitra A. Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res. 2003, 63, 7032-7037.
74. Ko S.Y.; Lin S.C.; Chang K.W.; Wong Y.K.; Liu C.J.; Chi C.W.; Liu T.Y. Increased expression of amyloid precursor protein in oral squamous cell carcinoma. Int. J. Cancer 2004, 111, 727-732.
75. Arvidsson Y.; Andersson E.; Bergström A.; Andersson M.K.; Altiparmak G.; Illerskog A.C.; Ahlman H.; Lamazhapova D.; Nilsson O. Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. Endocr. Relat. Cancer 2008, 15, 569-581.
76. Krause K.; Karger S.; Sheu S.Y.; Aigner T.; Kursawe R.; Gimm O.; Schmid K.W.; Dralle H.; Fuhrer D. Evidence for a role of the amyloid precursor protein in thyroid carcinogenesis. J. Endocrinol. 2008, 198, 291-299.
77. Cole S.L.; Vassar R. The Basic Biology of BACE1: A key therapeutic target for Alzheimer's disease. Curr. Genomics 2007, 8, 509-530.
78. Li R.; Lindholm K.; Yang L.B.; Yue X.; Citron M.; Yan R.; Beach T.; Sue L.; Sabbagh M.; Cai H.; et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA 2004, 101, 3632-3637.
79. Lee M.; Park J.J.; Ko Y.G.; Lee Y.S. Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-Anchored ST6Gal I-mediated sialylation of integrin β1 and migration in colon cancer cells. Radiat. Oncol. 2012, 7, 47.
80. Morris L.G.; Veeriah S.; Chan T.A. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 2010, 29, 3453-3464.
81. Salmena L.; Carracedo A.; Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133, 403-414.
82. Wong K.K.; Engelman J.A.; Cantley L.C. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 2010, 20, 87-90.
83. Veeriah S.; Taylor B.S.; Meng S.; Fang F.; Yilmaz E.; Vivanco I.; Janakiraman M.; Schultz N.; Hanrahan A.J.; Pao W.; et al. Somatic mutations of the Parkinson's disease-Associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet. 2010, 42, 77-82.
84. Shioya M.; Obayashi S.; Tabunoki H.; Arima K.; Saito Y.; Ishida T.; Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 2010, 36, 320-330.
85. Fabbri M.; Garzon R.; Cimmino A.; Liu Z.; Zanesi N.; Callegari E.; Liu S.; Alder H.; Costinean S.; Fernandez-Cymering C.; et al. microRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104, 15805-15810.
86. Garzon R.; Liu S.; Fabbri M.; Liu Z.; Heaphy C.E.; Callegari E.; Schwind S.; Pang J.; Yu J.; Muthusamy N.; et al. microRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113, 6411-6418.
87. Niwa R.; Zhou F.; Li C.; Slack F.J. The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans. Dev. Biol. 2008, 315, 418-425.
88. Johnson S.M.; Grosshans H.; Shingara J.; Byrom M.; Jarvis R.; Cheng A.; Labourier E.; Reinert K.L.; Brown D.; Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120, 635-647.
89. Lee Y.S.; Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21, 1025-1030.
90. Sampson V.B.; Rong N.H.; Han J.; Yang Q.; Aris V.; Soteropoulos P.; Petrelli N.J.; Dunn S.P.; Krueger L.J. microRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67, 9762-9770.
91. Boyerinas B.; Park S.M.; Hau A.; Murmann A.E.; Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17, F19-F36.
92. Hébert S.S.; Horré K.; Nicolaï L.; Bergmans B.; Papadopoulou A.S.; Delacourte A.; de Strooper B. microRNA regulation of Alzheimer's amyloid precursor protein expression. Neurobiol. Dis. 2009, 33, 422-428.
93. Poliseno L.; Salmena L.; Riccardi L.; Fornari A.; Song M.S.; Hobbs R.M.; Sportoletti P.; Varmeh S.; Egia A.; Fedele G.; et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-Targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 2010, 3, ra29.
94. Ivanovska I.; Ball A.S.; Diaz R.L.; Magnus J.F.; Kibukawa M.; Schelter J.M.; Kobayashi S.V.; Lim L.; Burchard J.; Jackson A.L.; et al. microRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol. Cell. Biol. 2008, 28, 2167-2174.
95. Pan S.; Yu F.; Gong C.; Song E. Tumor Invasion, and metastasis initiated by miR-106b in breast cancer by targeting BRMS1 and RB. Cancer Res. 2009, 69, 6157.
96. Kim J.; Inoue K.; Ishii J.; Vanti W.B.; Voronov S.V.; Murchison E.; Hannon G.; Abeliovich A. A microRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317, 1220-1224.
97. Lim L.P.; Lau N.C.; Garrett-Engele P.; Grimson A.; Schelter J.M.; Castle J.; Bartel D.P.; Linsley P.S.; Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433, 769-773.
98. Simunovic F.; Yi M.; Wang Y.; Macey L.; Brown L.T.; Krichevsky A.M.; Andersen S.L.; Stephens R.M.; Benes F.M.; Sonntag K.C. Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson's disease pathology. Brain 2009, 132, 1795-1809.
99. Lujambio A.; Ropero S.; Ballestar E.; Fraga M.F.; Cerrato C.; Setién F.; Casado S.; Suarez-Gauthier A.; Sanchez-Cespedes M.; Git A.; et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67, 1424-1429.
100. Bandrés E.; Cubedo E.; Agirre X.; Malumbres R.; Zárate R.; Ramirez N.; Abajo A.; Navarro A.; Moreno I.; Monzó M.; et al. Identification by real-Time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-Tumoral tissues. Mol. Cancer 2006, 5, 29.
101. Crawford M.; Batte K.; Yu L.; Wu X.; Nuovo G.J.; Marsh C.B.; Otterson G.A.; Nana-Sinkam S.P. microRNA 133B targets prosurvival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 2009, 388, 483-489.
102. Kano M.; Seki N.; Kikkawa N.; Fujimura L.; Hoshino I.; Akutsu Y.; Chiyomaru T.; Enokida H.; Nakagawa M.; Matsubara H. miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer 2010, 127, 2804-2814.
103. Hu G.; Chen D.; Li X.; Yang K.; Wang H.; Wu W. miR-133b regulates the MET protooncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10, 190-197.